Product Description
Caspofungin injection is used in adults and children 3 months of age and older to treat yeast infections in the blood, stomach, lungs, and esophagus (tube that connects the throat to the stomach.) and certain fungal infections that could not be treated successfully with other medications. (Sourced from: https://medlineplus.gov/druginfo/meds/a615001.html)
Mechanisms of Action: Glucan Synthase Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, South Africa, Unknown Location
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Candidemia|Candidiasis, Invasive|Candidiasis, Oral
Phase 2: Communicable Diseases|Pneumocystis Infections|Pneumonia, Pneumocystis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CaspoNEB | P2 |
Not yet recruiting |
Pneumonia, Pneumocystis|Communicable Diseases|Pneumocystis Infections |
2026-06-01 |
|
| CTR20223058 | P3 |
Not yet recruiting |
Candidiasis, Invasive|Candidiasis, Oral|Candidemia |
None |